ArQule Gets $30 Million Up Front From Kyowa In Oncology Deal
This article was originally published in PharmAsia News
Executive Summary
ArQule's agreement with Tokyo biotech Kyowa to develop and commercialize Phase I oncology molecule ARQ 197 in Asia will give the firm a much-needed cash infusion to support the product's development in the U.S